This is the first Australian case series on MMS for DFSP. Our findings demonstrate no recurrences with follow-up and demonstrate that MMS may achieve clearance with smaller clinical margins than WLE. These results support international guidelines recommending MMS as the gold-standard treatment and highlight the need to improve access to MMS in Australia.
Johns et al. (Mon,) studied this question.